U.S. Patent No. 10,625,177 B2 (‘177) issued on April 21, 2020, for “Bioavailable Cannabis Plant Blend.” It was issued to inventor David Harold Moore of Henderson, Nevada.
The inventor discusses in the background of the specification how he has Asperger’s Syndrome, a mild form of autism. This autism can lead to an autoimmune disorder causing celiac disease, which can develop into renal disease. The ‘177 patent is the inventor’s own research into developing a process to use cannabis as a food product to alleviate issues related to the celiac disease. The sole claim is directed to the method of processing raw cannabis plant into a frozen form through essentially dehumidying the cannabis matter between 200-350°F for 1 minute to up to 3 hours; then further heating the dehumidified matter, then freezing the matter four more times. The only drawing illustrates the decarboxylated THCA through the heating processes.
The Cooperative Patent Classifications are A61K, preparations for medical, dental, or toilet purposes, namely medicinal preparations of undetermined constitution containing material from algae, licens, fungi or plants (36/00) and, e.g., traditional herbal medicines, like magnoliopsida (36/185); B01D, separation of solids by wet methods, namely, separation of liquids, not provided elsewhere, e.g., by thermal diffusion (17/00); and C07D, heterocyclic compounds, namely, heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other ring systems having three or more relevant rings, e.g., dibenzopyrams (311/80).
For more information on patenting for cannabis-related inventions, please contact Yonaxis IP.